Agios Pharma Reports Received FDA Breakthrough Therapy Designation For TIBSOVO In Combo With Azacitidine For Treatment Of Newly-Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy